모구 형질세포양 수지상세포 종양(BPDCN) : 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(2025-2035년)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market Outlook

Thelansis's "Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Blastic Plasmacytoid Dendritic Cell Neoplasm treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Overview

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy with a poor prognosis, arising from precursors of plasmacytoid dendritic cells. It most commonly presents with cutaneous involvement, where patients develop asymptomatic lesions ranging from bruise-like patches to plaques or nodules, often involving large body areas.

Beyond the skin, BPDCN frequently involves the bone marrow, lymph nodes, spleen, and central nervous system (CNS), leading to systemic disease manifestations including cytopenias and organ infiltration. It is classified under dendritic cell and histiocytic neoplasms and is often associated with or evolves into other hematologic malignancies.

The disease predominantly affects older adults, with a strong male predominance (male-to-female ratio ~3:1 to 5:1), and is typically diagnosed between 60-70 years of age. Despite advances, BPDCN remains clinically challenging due to its aggressive nature, high relapse rates, and limited long-term treatment options.

Key Highlights

• BPDCN is a rare, aggressive hematologic malignancy with high unmet need
• US incidence expected to increase from ~1.8K to ~2.4K (~3% CAGR)

Market Overview

• France market projected to grow from ~$8.3M to ~$17.4M (~7-8% CAGR)
• Growth driven by targeted therapies and improved diagnosis, despite small patient population

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Chongqing Precision Biotech Co. Ltd
• AbbVie
• Stemline Therapeutics

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)